Aquestive Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Aquestive Therapeutics es Dan Barber , nombrado en May 2022, tiene una permanencia de 2.5 años. compensación anual total es $2.50M, compuesta por 24% salario y 76% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.52% de las acciones de la empresa, por valor de $6.24M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 2.2 años, respectivamente.
Información clave
Dan Barber
Chief Executive Officer (CEO)
US$2.5m
Compensación total
| Porcentaje del salario del CEO | 24.0% |
| Permanencia del CEO | 2.5yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 2.3yrs |
| Promedio de permanencia en la Junta Directiva | 2.2yrs |
Actualizaciones recientes de la dirección
Recent updates
Aquestive: Rare Opportunity With Dual Platform Strategy
Nov 05Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Sep 07
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Aug 20Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$600k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$542k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$1m | US$424k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$840k | US$410k | -US$56m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$50m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$1m | US$389k | -US$66m |
| Sep 30 2019 | n/a | n/a | -US$68m |
| Jun 30 2019 | n/a | n/a | -US$64m |
| Mar 31 2019 | n/a | n/a | -US$80m |
| Dec 31 2018 | US$2m | US$319k | -US$61m |
| Sep 30 2018 | n/a | n/a | -US$61m |
| Jun 30 2018 | n/a | n/a | -US$38m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$899k | US$300k | -US$14m |
Compensación vs. Mercado: La compensación total ($USD2.50M) de Dan está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD2.24M).
Compensación vs. Ingresos: La compensación de Dan ha aumentado mientras la empresa no es rentable.
CEO
Dan Barber (48 yo)
2.5yrs
Permanencia
US$2,496,141
Compensación
Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 6.2m | |
| Chief Financial Officer | 3.9yrs | US$1.12m | 0.43% $ 1.8m | |
| General Counsel | 6.2yrs | US$1.19m | 0.52% $ 2.2m | |
| Chief Operating Officer | 2yrs | sin datos | 0.25% $ 1.0m | |
| Chief Innovation & Technology Officer | 9.9yrs | US$810.02k | 1.08% $ 4.4m | |
| Chief Science Officer | no data | sin datos | 0.28% $ 1.2m | |
| Senior Vice President of Sales & Marketing | less than a year | sin datos | 0.027% $ 112.8k | |
| Senior Vice President of Information Technology & Human Resources | 1.7yrs | sin datos | 0.26% $ 1.1m | |
| Chief Medical Officer | no data | sin datos | sin datos | |
| Chief Medical Officer | 1.4yrs | sin datos | 0.28% $ 1.1m | |
| VP of Finance | no data | sin datos | sin datos |
2.3yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de AQST se considera experimentado (2.3 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO, President & Director | 2.5yrs | US$2.50m | 1.52% $ 6.2m | |
| Independent Director | 2.3yrs | US$145.23k | 0% $ 0 | |
| Independent Chairman of the Board | 17.7yrs | US$150.77k | 0.082% $ 338.6k | |
| Independent Director | 3.8yrs | US$137.69k | 0% $ 0 | |
| Independent Vice Chairman of the Board | 20.8yrs | US$137.23k | 0.11% $ 448.7k | |
| Independent Director | 3.8yrs | US$121.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos | |
| Member of Scientific Advisory Board | 2.2yrs | sin datos | sin datos |
2.2yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de AQST no se considera experimentada (2.2 años de permanencia promedio), lo que sugiere una nueva junta directiva.